The 3CTN EDI Framework and Toolkit is Launched
The Canadian Cancer Clinical Trials Network (3CTN) and its collaborative partners are thrilled to announce the launch of an Equity, Diversity, and Inclusion (EDI) Framework and companion Toolkit designed to support the Canadian research community in embedding EDI best practices within clinical trial conduct! This comprehensive EDI Framework and Toolkit resource are the products of an expert working group comprised of 3CTN members, trial sponsors, and people with lived experience from underrepresented communities. The resulting materials are available and accessible on the 3CTN website for the benefit of all in the research community. To access, please go to https://3ctn.ca/equity-diversity-and-inclusion-in-clinical-trials/.
New CCRA Advisory Board Chair and Elected Representative
Effective January 1, 2026, CCRA welcomes new CCRA Advisory Board chair, Dr. James (Jim) Woodgett. Jim is the President and Scientific Director of the Terry Fox Research Institute (TFRI), a Senior Scientist at the Lunenfeld-Tanenbaum Research Institute at Sinai... Read More »
Effective January 1, 2026, CCRA welcomes new CCRA Advisory Board chair, Dr. James (Jim) Woodgett. Jim is the President and Scientific Director of the Terry Fox Research Institute (TFRI), a Senior Scientist at the Lunenfeld-Tanenbaum Research Institute at Sinai... Read More »
Refreshed CCRA Advisory Board
Effective January 1st, 2021, CCRA welcomes new Advisory Board chair, Dr. Paula Robson. Paula is the Scientific Director of the Cancer Strategic Clinical Network, and Scientific Director and co-lead of Cancer Research & Analytics for Cancer Care Alberta in Alberta Health Services.... Read More »
Effective January 1st, 2021, CCRA welcomes new Advisory Board chair, Dr. Paula Robson. Paula is the Scientific Director of the Cancer Strategic Clinical Network, and Scientific Director and co-lead of Cancer Research & Analytics for Cancer Care Alberta in Alberta Health Services.... Read More »